CD123

Assets acting on this target.

Class
CD123-targeted recombinant fusion protein toxin (IL-3 fused to truncated diphtheria toxin)
Pathway
CD123-mediated internalization followed by ADP-ribosylation of eEF2, halting protein synthesis and inducing apoptosis
Notes
original target text: CD123 (IL3RA)

CD123, also known as the interleukin-3 receptor alpha chain (IL3RA), is a cell-surface receptor expressed at low levels on normal blood-forming cells but markedly elevated on the malignant cells of certain blood cancers, including blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia. Because this overexpression is relatively selective, CD123 has become an attractive handle for directing cytotoxic payloads specifically to malignant cells while limiting exposure to healthy tissue. One engineering approach fuses the receptor's natural ligand, interleukin-3, to a truncated bacterial toxin derived from diphtheria toxin. When this fusion protein binds CD123, the complex is taken into the cell through receptor-mediated internalization; once inside, the toxin portion chemically modifies a protein synthesis factor, halting the cell's ability to make new proteins and triggering programmed cell death. This mechanism does not depend on triggering the receptor's normal growth-signaling function, but rather exploits it purely as an entry point for the toxin. Beyond toxin fusions, CD123 is also targeted by antibody-drug conjugates, chimeric antigen receptor cell therapies, and other engineered constructs, reflecting broad interest in this receptor across modalities for hematologic malignancies where leukemic stem cells and blasts depend on its expression.

By indication

Related mechanisms

CD123 drugs compared

5 drugs, stage by indication
5 drugs acting on CD123: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
Pivekimab SunirineDecnupazAbbVieantibody-drug conjugatePhase 2/3Phase 2/3 in Acute Myeloid Leukemia
TagraxofuspStemline Therapeutics, Inc.fusion proteinPhase 2Phase 2 in Acute Myeloid Leukemia
CD123 targeted CAR-NK cellsChongqing Precision Biotech Co., Ltdcell therapy (CAR-NK)Phase 1/2Phase 1/2 in Acute Myeloid Leukemia
Allo-RevCAR01-TAvenCell Europe GmbHCAR-TPhase 1Phase 1 in Acute Myeloid Leukemia
BYON4413Byondis B.V.antibody-drug conjugatePhase 1Phase 1 in Acute Myeloid Leukemia

← all mechanisms